Two KOLs will discuss recent quantitative
market research on the use of anticoagulants in the dialysis
circuit
Discussion will also focus on the Niyad study
protocol for upcoming NEPHRO Study
Register to attend the webcast event on
December 6, 2023 at 11:00 a.m. ET
SAN
MATEO, Calif., Nov. 7, 2023
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),
(AcelRx), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for use
in medically supervised settings, today announced that it will host
a virtual Key Opinion Leader (KOL) panel discussion on its lead
candidate Niyad™ (nafamostat) for use as an anticoagulant in
dialysis circuits. The panel will feature two thought-leaders in
the nephrology and critical care fields who are also co-authors on
a recent market research manuscript reporting current issues with
anticoagulants in the dialysis circuit. The panel will also discuss
the NEPHRO CRRT (Nafamostat Efficacy
in Phase 3 Registrational
Continuous Renal Replacement Therapy)
Study, a registrational study comparing Niyad with placebo for
dialysis circuit anticoagulation, which is planned to start in the
fourth quarter. Both panel members are principal investigators in
the trial.
The webcasted event will take place on Wednesday, December 6, 2023 at 11:00 a.m. ET / 8:00 a.m.
PT.
To register for the event, click here.
The event will include a discussion led by Pamela Palmer, M.D., Ph.D., co-founder and Chief
Medical Officer of AcelRx, and features KOLs Laurence Busse M.D.,
M.B.A. (Emory University School of
Medicine) and David W. Boldt,
M.D. (UCLA Medical Center).
A live question and answer will follow the discussion.
About Laurence Busse M.D.,
M.B.A.
Laurence Busse MD, MBA, completed
his medical education at George Washington
University, where he stayed on for his Internal Medicine
residency, and fellowship training in Critical Care Medicine. He
worked as an Intensivist in northern Virginia before joining Emory University in 2016 as the Medical Director of
critical care at Emory Saint Joseph's Hospital. He currently serves
as Medical Director for critical care at Emory Johns Creek
Hospital. Prior to his medical career, Dr. Busse received his
Masters degree in Business Administration from Emory University. His areas of research and
interest include the examination of the sequelae of high output
shock, including catecholamine resistant hypotension and acute
kidney injury. Dr. Busse has been involved in early clinical work
exploring the use of angiotensin II as a novel therapeutic agent in
catecholamine resistant hypotension. He is actively engaged as an
intensivist and supervises trainees in Emory Johns Creek Hospital's
intensive care unit.
About David W. Boldt,
M.D.
David W. Boldt, MD is an
Anesthesiologist and Critical Care Intensivist at UCLA Medical
Center in Los Angeles, CA. He
divides his clinical time between the operating room, where he is
the Division Chief of Trauma and Adult Multi-specialty
Anesthesiology, and the Cardiothoracic Intensive Care Unit, where
he takes care of patients after heart and lung surgery including
transplants and mechanical circulatory support, such as
extracorporeal membrane oxygenation. He is an avid clinical
researcher in both the operating room and ICU on topics such as
acute kidney injury, sepsis, vasoconstrictor therapy, atrial
fibrillation, and ECMO. Dr. Boldt has been invited as a speaker
both nationally and internationally, including being faculty and
three-time speaker at the International Society of Intensive Care
and Emergency Medicine, which is held annually in Brussels, Belgium, and is the largest meeting
of critical care and emergency medicine in the world.
About Nafamostat
Nafamostat is a broad spectrum, synthetic serine protease
inhibitor with anticoagulant, anti-inflammatory and potential
anti-viral activities. Niyad™ is a lyophilized formulation of
nafamostat and is currently being studied under an investigational
device exemption, or IDE, as an anticoagulant for the
extracorporeal circuit, and has received Breakthrough Device
Designation Status from the FDA. LTX-608 is a proprietary
nafamostat formulation for direct IV infusion that will be
investigated and developed as a potential anti-viral for the
treatment of COVID, acute respiratory distress syndrome (ARDS),
disseminated intravascular coagulation (DIC) and acute
pancreatitis.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's lead product candidate, Niyad™ is a lyophilized
formulation of nafamostat and is currently being studied under an
investigational device exemption, or IDE, as an anticoagulant for
the extracorporeal circuit, and has received Breakthrough Device
Designation status from the FDA. AcelRx is also developing two
pre-filled syringes in-licensed from its partner Aguettant:
Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled
phenylephrine syringe. This release is intended for investors only.
For additional information about AcelRx, please visit
www.acelrx.com.
Forward-looking statements
This press release contains forward-looking statements based
upon AcelRx's current expectations. These and any other
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking
terminology such as "potential", "believe", "expect", "expects",
"expected", "anticipate", "upcoming", "may", "will",
"enable," "should," "seek", "approximately", "intends", "intended",
"plans", "planned", "planning", "estimates", "benefits", or the
negative of these words or other comparable terminology. The
discussion of strategy, plans or intentions may also include
forward-looking statements, which are predictions, projections and
other statements about future events that are based on current
expectations and assumptions. These forward-looking statements
involve risks and uncertainties that could cause actual results to
differ materially from those projected, anticipated or implied by
such statements, including: (i) risks relating to AcelRx's product
development activities and ongoing commercial business operations;
(ii) risks related to the ability of AcelRx and its business
partners to implement development plans, launch plans, forecasts
and other business expectations; (iii) risks related to unexpected
variations in market growth and demand for AcelRx's commercial and
developmental products and technologies; (iv) risks related to
AcelRx's liquidity and its ability to maintain capital resources
sufficient to conduct the required clinical studies; (v) AcelRx's
ability to retain its listing on the Nasdaq exchange; and (vi)
risks relating to AcelRx's ability to obtain regulatory approvals
for its developmental product candidates. Although it is not
possible to predict or identify all such risks and uncertainties,
they may include, but are not limited to, those described under the
caption "Risk Factors" and elsewhere in AcelRx's annual, quarterly
and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as
filed or furnished with the Securities and Exchange Commission
(SEC) and any subsequent public filings. You are cautioned not to
place undue reliance on any such forward-looking statements, which
speak only as of the date such statements were first made. To the
degree financial information is included in this press release, it
is in summary form only and must be considered in the context of
the full details provided in AcelRx's most recent annual, quarterly
or current report as filed or furnished with the SEC. AcelRx's SEC
reports are available at www.acelrx.com under the "Investors" tab.
Except to the extent required by law, AcelRx undertakes no
obligation to publicly release the result of any revisions to these
forward-looking statements to reflect new information, events or
circumstances after the date hereof, or to reflect the occurrence
of unanticipated events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-kol-panel-discussion-on-current-anticoagulant-use-in-dialysis-and-the-upcoming-niyad-clinical-study-301980608.html
SOURCE AcelRx Pharmaceuticals, Inc.